AGO TUMOR - AN OVERVIEW

Molecular typing relies on molecular genetic testing and isn't but routinely available. Molecular subtypes and immunohistochemical surrogate markers of your tumors (HR, HER2, triple negative) correlate in about 70%. The differentiation of luminal A and B subtypes by HR status and proliferation markers like Ki-67 could be useful, but a potential val